Tranexamic Acid in Dacryocystorhinostomy

Single Dose Tranexamic Acid for Dacryocystorhinostomy

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01221909

Acronym

TA-DCR

Enrollment

Registered

2010-10-15

Start date

2010-12-31

Completion date

2012-12-31

Last updated

2010-10-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nasolacrimal Tract Obstruction

Keywords

bleeding, dacryocystorhinostomy, operative duration

Brief summary

Single dose tranexamic acid (TA) before dacryocystorhinostomy (DCR) operation: a prospective, double blind, placebo controlled study. The study hypothesis: TA in DCR might reduce the intraoperative and postoperative bleeding in DCR surgery, and might reduce the duration of the surgery.

Interventions

DRUGTranexamic acid

Single dose TA 500mg or placebo will be given in DCR surgery right after the first surgical incision.

DRUGsaline solution

5cc saline solution

Study design

Allocation

RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

PREVENTION

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* obstruction of nasolacrimal pathway * eligible for DCR surgery * 18 years of age or older

Exclusion criteria

* warfarin treatment * renal insufficiency * pregnancy * mental retardation * tendency to bleed * thromboembolic disease * thrombophilia

Design outcomes

Primary

Measure	Time frame
Duration of DCR surgery in minutes and amount of blood loss in milliliters during surgery.	Blood loss will be measured at the end of DCR operation from the suction bowel. Duration of surgery will be caculated by registering time of operation start and end.

Secondary

Measure	Time frame
Late onset postoperative epistaxis or periorbital hematoma	8 days

Countries

Israel

Contacts

Primary ContactHaneen Jabaly-Habib, M.D.

hjabaly@gmail.com972-506268059

Backup ContactAbed Mukari, M.D.

amukari@gmail.com972-546881532

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026